GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Yunkang Group Ltd (HKSE:02325) » Definitions » Debt-to-EBITDA

Yunkang Group (HKSE:02325) Debt-to-EBITDA : -6.20 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Yunkang Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Yunkang Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,280.1 Mil. Yunkang Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$240.1 Mil. Yunkang Group's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-245.2 Mil. Yunkang Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -6.20.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Yunkang Group's Debt-to-EBITDA or its related term are showing as below:

HKSE:02325' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -32.13   Med: 3.6   Max: 125.75
Current: -32.13

During the past 6 years, the highest Debt-to-EBITDA Ratio of Yunkang Group was 125.75. The lowest was -32.13. And the median was 3.60.

HKSE:02325's Debt-to-EBITDA is ranked worse than
100% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.79 vs HKSE:02325: -32.13

Yunkang Group Debt-to-EBITDA Historical Data

The historical data trend for Yunkang Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yunkang Group Debt-to-EBITDA Chart

Yunkang Group Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 5.90 1.30 0.69 1.27 55.44

Yunkang Group Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only 0.65 0.88 2.29 7.28 -6.20

Competitive Comparison of Yunkang Group's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Yunkang Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yunkang Group's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Yunkang Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Yunkang Group's Debt-to-EBITDA falls into.



Yunkang Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Yunkang Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1280.118 + 240.058) / 27.42
=55.44

Yunkang Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1280.118 + 240.058) / -245.164
=-6.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Yunkang Group  (HKSE:02325) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Yunkang Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Yunkang Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Yunkang Group (HKSE:02325) Business Description

Traded in Other Exchanges
N/A
Address
No. 6 Lizhishan Road, Science City, Huangpu District, Guangzhou, CHN
Yunkang Group Ltd is a medical operation service provider in China. The company has three major business lines namely covering diagnostic testing services for medical consortia, diagnostic outsourcing services, and non-medical institutions.
Executives
Huizekx Limited 2201 Interest of corporation controlled by you
Yk Development Limited 2101 Beneficial owner
Zhang Yong 2201 Interest of corporation controlled by you
Shanghai Pudong Development Bank Co., Ltd 2201 Interest of corporation controlled by you
Zhou Xinyu
Guang Zhou Da An Ji Yin Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Da An Guo Ji Ji Tuan You Xian Gong Si 2101 Beneficial owner
Guang Zhou Shi Da An Ji Yin Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Jin Jun Ying Limited 2201 Interest of corporation controlled by you
Mouduans Limited 2201 Interest of corporation controlled by you
Source Capital Rw Limited 2201 Interest of corporation controlled by you
Tongfuzc Limited 2201 Interest of corporation controlled by you
Wjjr Investment Limited 2201 Interest of corporation controlled by you

Yunkang Group (HKSE:02325) Headlines

No Headlines